Lotte Biologics has strengthened its environmental, social, and governance (ESG) competitiveness in the global contract development and manufacturing organization (CDMO) market by receiving recognition for the eco-friendly construction of its first plant at the Incheon Bio Campus.
On August 25, Lotte Biologics announced that it has obtained an 'Excellent' grade in the national green building certification (G-SEED) from the Korea Institute of Eco-Friendly Architecture for its first plant at the Incheon Bio Campus.
The green building certification is a national program jointly operated by the Ministry of Land, Infrastructure and Transport and the Ministry of Environment. It comprehensively evaluates energy and resource savings, as well as pollution reduction, throughout the entire process from material production to design, construction, and maintenance. Lotte Biologics achieved the excellent grade after a comprehensive assessment in seven areas, including land use and transportation, energy and environmental pollution, materials and resources, water circulation management, maintenance, and ecological environment.
From the design phase of the first plant at the Incheon Bio Campus, Lotte Biologics incorporated eco-friendly construction elements and established a management system aimed at achieving an excellent grade during the preliminary certification stage. Throughout the construction process, the company continuously checked and improved key evaluation criteria, such as the use of eco-friendly materials and the introduction of energy-efficient facilities.
Lotte Biologics plans to expand the application of eco-friendly construction principles to future production facilities, starting with the first plant at the Incheon Bio Campus, to enhance its ESG management. The first plant spans a total area of 99,558 square meters and is equipped with eight 15,000-liter bioreactors, providing a total production capacity of 120,000 liters for antibody drugs.
Currently, the first plant is undergoing a qualification evaluation (C&Q) for its equipment and utilities. The company plans to establish a good manufacturing practice (GMP) production system that meets global regulatory standards after conducting trial operations and verifying manufacturing and quality systems in the second half of this year, with commercial production set to begin next year.
A representative from Lotte Biologics stated, "The first plant at the Incheon Bio Campus was built considering not only production capacity and quality competitiveness but also a sustainable production environment. With this certification, we will continue to build production infrastructure that considers eco-friendly elements and strengthen our CDMO capabilities to meet the diverse needs of global clients."
Meanwhile, Lotte Biologics has recently completed the relocation of all employees to the Incheon Bio Campus. The company aims to consolidate its previously dispersed headquarters and production functions in one location to accelerate preparations for the commercial production of the first plant next year.
This relocation has brought together key organizations, including management, production, quality, engineering, and business development, at the production site. Lotte Biologics expects that this will enhance decision-making speed during the commercial production preparation process, including technology transfer, process readiness, and quality review, and allow for quick responses to issues arising on the production floor.
On August 25, Lotte Biologics announced that it has obtained an 'Excellent' grade in the national green building certification (G-SEED) from the Korea Institute of Eco-Friendly Architecture for its first plant at the Incheon Bio Campus.
The green building certification is a national program jointly operated by the Ministry of Land, Infrastructure and Transport and the Ministry of Environment. It comprehensively evaluates energy and resource savings, as well as pollution reduction, throughout the entire process from material production to design, construction, and maintenance. Lotte Biologics achieved the excellent grade after a comprehensive assessment in seven areas, including land use and transportation, energy and environmental pollution, materials and resources, water circulation management, maintenance, and ecological environment.
From the design phase of the first plant at the Incheon Bio Campus, Lotte Biologics incorporated eco-friendly construction elements and established a management system aimed at achieving an excellent grade during the preliminary certification stage. Throughout the construction process, the company continuously checked and improved key evaluation criteria, such as the use of eco-friendly materials and the introduction of energy-efficient facilities.
Lotte Biologics plans to expand the application of eco-friendly construction principles to future production facilities, starting with the first plant at the Incheon Bio Campus, to enhance its ESG management. The first plant spans a total area of 99,558 square meters and is equipped with eight 15,000-liter bioreactors, providing a total production capacity of 120,000 liters for antibody drugs.
Currently, the first plant is undergoing a qualification evaluation (C&Q) for its equipment and utilities. The company plans to establish a good manufacturing practice (GMP) production system that meets global regulatory standards after conducting trial operations and verifying manufacturing and quality systems in the second half of this year, with commercial production set to begin next year.
A representative from Lotte Biologics stated, "The first plant at the Incheon Bio Campus was built considering not only production capacity and quality competitiveness but also a sustainable production environment. With this certification, we will continue to build production infrastructure that considers eco-friendly elements and strengthen our CDMO capabilities to meet the diverse needs of global clients."
Meanwhile, Lotte Biologics has recently completed the relocation of all employees to the Incheon Bio Campus. The company aims to consolidate its previously dispersed headquarters and production functions in one location to accelerate preparations for the commercial production of the first plant next year.
This relocation has brought together key organizations, including management, production, quality, engineering, and business development, at the production site. Lotte Biologics expects that this will enhance decision-making speed during the commercial production preparation process, including technology transfer, process readiness, and quality review, and allow for quick responses to issues arising on the production floor.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.